Literature DB >> 9871430

Grapefruit juice substantially increases plasma concentrations of buspirone.

J J Lilja1, K T Kivistö, J T Backman, T S Lamberg, P J Neuvonen.   

Abstract

BACKGROUND: Buspirone has a low oral bioavailability because of extensive first-pass metabolism. The effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of orally administered buspirone is not known.
METHODS: In a randomized, 2-phase crossover study, 10 healthy volunteers took either 200 mL double-strength grapefruit juice or water 3 times a day for 2 days. On day 3, each subject ingested 10 mg buspirone with either 200 mL grapefruit juice or water, and an additional 200 mL was ingested 1/2 hour and 1 1/2 hours after buspirone administration. Timed blood samples were collected up to 12 hours after ingestion, and the effects of buspirone were measured with 6 psychomotor tests up to 8 hours after ingestion.
RESULTS: Grapefruit juice increased the mean peak plasma concentration of buspirone 4.3-fold (range, 2-fold to 15.6-fold; P < .01) and the mean area under the plasma buspirone concentration-time curve 9.2-fold (range, 3-fold to 20.4-fold; P < .01). The time of the peak concentration (tmax) of buspirone increased from 0.75 to 3 hours (P < .01), and the elimination half-life (t1/2) was slightly increased (P < .01) by grapefruit juice. A significant increase in the pharmacodynamic effects of buspirone by grapefruit juice was seen only in subjective overall drug effect (P < .01).
CONCLUSIONS: Grapefruit juice considerably increased plasma buspirone concentrations. The probable mechanism of this interaction is delayed gastric emptying and inhibition of the cytochrome P450 3A4-mediated first-pass metabolism of buspirone caused by grapefruit juice. Concomitant use of buspirone and at least large amounts of grapefruit juice should be avoided.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9871430     DOI: 10.1016/S0009-9236(98)90056-X

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Interaction between grapefruit juice and praziquantel in humans.

Authors:  Nelly Castro; Helgi Jung; Roberto Medina; Dinora González-Esquivel; Mario Lopez; Julio Sotelo
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

2.  Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin.

Authors:  Sara K Quinney; Srikar R Malireddy; Raj Vuppalanchi; Mitchell A Hamman; Naga Chalasani; J Christopher Gorski; Stephen D Hall
Journal:  Eur J Clin Pharmacol       Date:  2012-07-10       Impact factor: 2.953

3.  S-ketamine concentrations are greatly increased by grapefruit juice.

Authors:  Marko A Peltoniemi; Teijo I Saari; Nora M Hagelberg; Kari Laine; Pertti J Neuvonen; Klaus T Olkkola
Journal:  Eur J Clin Pharmacol       Date:  2012-06       Impact factor: 2.953

4.  Effects of orange juice on the pharmacokinetics of atenolol.

Authors:  J J Lilja; K Raaska; P J Neuvonen
Journal:  Eur J Clin Pharmacol       Date:  2005-06-28       Impact factor: 2.953

5.  Cranberry juice suppressed the diclofenac metabolism by human liver microsomes, but not in healthy human subjects.

Authors:  Kentarou Ushijima; Shu-ichi Tsuruoka; Hidetoshi Tsuda; Gohki Hasegawa; Yuri Obi; Tae Kaneda; Masaki Takahashi; Tomohiro Maekawa; Tomohiro Sasaki; Taka-aki Koshimizu; Akio Fujimura
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

6.  Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.

Authors:  Garrett R Ainslie; Kristina K Wolf; Yingxin Li; Elizabeth A Connolly; Yolanda V Scarlett; J Heyward Hull; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2014-09-24       Impact factor: 4.030

Review 7.  Undesirable effects of citrus juice on the pharmacokinetics of drugs: focus on recent studies.

Authors:  Mitsuo Saito; Mutsuko Hirata-Koizumi; Mariko Matsumoto; Tsutomu Urano; Ryuichi Hasegawa
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

8.  Prediction of nonlinear intestinal absorption of CYP3A4 and P-glycoprotein substrates from their in vitro Km values.

Authors:  Tatsuhiko Tachibana; Motohiro Kato; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2011-09-13       Impact factor: 4.200

9.  Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.

Authors:  Kiyohi Natsui; Yoshiko Mizuno; Naoko Tani; Masashi Yabuki; Setsuko Komuro
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Oct-Dec       Impact factor: 2.441

10.  Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.

Authors:  Kiyohi Natsui; Yoshiko Mizuno; Naoko Tani; Masashi Yabuki; Setsuko Komuro
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2007 Jul-Sep       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.